KCE-210

N/A

Report date: 2025/01/26 17:08:44

Base Information

Drug NameKCE-210

Drug Alias Nameanti-immunoglobulin E antibody fusion protein (Kissei Pharmaceutical)IgE receptor-IgG1 Fc fusion protein (Kissei Pharmaceutical)KCE-210

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunoglobulin E inhibitors

TargetsImmunoglobulin E

Therapy Area/IndicationsConjunctivitis, AllergicEye Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKissei Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesKissei Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsConjunctivitis, Allergic

Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A